What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for Sarepta Therapeutics in a report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will earn $2.30 per share for the year. HC Wainwright currently has a “Sell” rating and a $80.00 target price on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.07 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

A number of other analysts have also weighed in on the stock. Barclays lowered their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price for the company. UBS Group upped their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Guggenheim raised their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Trading Up 5.7 %

SRPT opened at $137.94 on Wednesday. Sarepta Therapeutics has a 1-year low of $78.67 and a 1-year high of $173.25. The firm has a 50-day moving average price of $121.90 and a two-hundred day moving average price of $131.39. The stock has a market capitalization of $13.18 billion, a PE ratio of 104.40 and a beta of 0.81. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Tidal Investments LLC raised its holdings in Sarepta Therapeutics by 8.5% during the first quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock worth $376,000 after acquiring an additional 228 shares in the last quarter. Castleark Management LLC bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $304,000. Comerica Bank boosted its holdings in shares of Sarepta Therapeutics by 489.4% in the 1st quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock valued at $432,000 after buying an additional 2,770 shares during the last quarter. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics in the first quarter valued at $32,000. Finally, Farallon Capital Management LLC increased its holdings in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.